MEP24008A - Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds - Google Patents

Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds

Info

Publication number
MEP24008A
MEP24008A MEP-240/08A MEP24008A MEP24008A ME P24008 A MEP24008 A ME P24008A ME P24008 A MEP24008 A ME P24008A ME P24008 A MEP24008 A ME P24008A
Authority
ME
Montenegro
Prior art keywords
carnitine
alkanoyl
esters
active compounds
pharmacologically active
Prior art date
Application number
MEP-240/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Claudio Pisano
Maria Ornella Tinti
Mose Santaniello
Luciana Critelli
Giovanni Salvatori
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of MEP24008A publication Critical patent/MEP24008A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MEP-240/08A 1999-04-13 2000-04-11 Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds MEP24008A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1999RM000220A IT1306129B1 (it) 1999-04-13 1999-04-13 Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
PCT/IT2000/000137 WO2000061543A2 (en) 1999-04-13 2000-04-11 Esters of l-carnitine or alkanoyl l-carnitines
YUP-702/01A RS50911B (sr) 1999-04-13 2000-04-11 Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobađanje farmakološki aktivnih jedinjenja

Publications (1)

Publication Number Publication Date
MEP24008A true MEP24008A (en) 2010-06-10

Family

ID=11406659

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-240/08A MEP24008A (en) 1999-04-13 2000-04-11 Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds
MEP-2008-240A ME00113B (me) 1999-04-13 2000-04-11 Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobađanje farmakološki aktivnih jedinjenja

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2008-240A ME00113B (me) 1999-04-13 2000-04-11 Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobađanje farmakološki aktivnih jedinjenja

Country Status (34)

Country Link
US (4) US6797281B1 (xx)
EP (3) EP1183228B1 (xx)
JP (2) JP4703855B2 (xx)
KR (2) KR100798499B1 (xx)
CN (2) CN1263730C (xx)
AT (2) ATE286873T1 (xx)
AU (2) AU776301B2 (xx)
BG (3) BG65501B1 (xx)
BR (2) BRPI0017460B1 (xx)
CA (2) CA2650202C (xx)
CZ (1) CZ302628B6 (xx)
DE (2) DE60017388T2 (xx)
DK (2) DK1426044T3 (xx)
EA (2) EA006021B1 (xx)
EE (2) EE05719B1 (xx)
ES (2) ES2258688T3 (xx)
HK (2) HK1045145B (xx)
HR (1) HRP20010740B1 (xx)
HU (1) HU229366B1 (xx)
IL (4) IL145765A0 (xx)
IS (2) IS2476B (xx)
IT (1) IT1306129B1 (xx)
ME (2) MEP24008A (xx)
MX (1) MXPA01010359A (xx)
NO (2) NO327742B1 (xx)
NZ (2) NZ528874A (xx)
PL (2) PL211710B1 (xx)
PT (2) PT1426044E (xx)
RS (3) RS50911B (xx)
SI (2) SI1183228T1 (xx)
SK (2) SK287253B6 (xx)
TR (2) TR200202358T2 (xx)
WO (1) WO2000061543A2 (xx)
ZA (1) ZA200109291B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4879433B2 (ja) * 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
DE10113446A1 (de) † 2001-03-19 2002-09-26 Schwarzkopf Gmbh Hans Haarbehandlungsmittel mit Betainen
PT2286795T (pt) * 2002-06-26 2017-01-27 Syncore Biotechnology Co Ltd Processo de produção de uma preparação lipossomal catiónica que compreende um composto lipófilo
WO2004002468A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Method of producing a cationic liposomal preparation comprising a lipophilic compound
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
EP1868571A4 (en) * 2005-03-02 2011-10-26 Univ Northeastern MITOCHONDRIOTROPIC PHOSPHOLIPIDE VESICLES
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
BRPI0614757A2 (pt) * 2005-08-10 2011-04-12 Novartis Ag composição farmacêutica, micropartìcula e seu uso
KR20080034149A (ko) * 2005-08-10 2008-04-18 노파르티스 아게 7-(ｔ-부톡시)이미노메틸 캄토테신에 대한 제형
WO2008024389A2 (en) * 2006-08-23 2008-02-28 Biodelivery Sciences International, Inc. Amphiphilic nucleotide cochleate compositions and methods of using the same
WO2008094959A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
WO2008101173A2 (en) * 2007-02-16 2008-08-21 Cornell University Biodegradable compositions and materials
US20100204432A1 (en) * 2007-05-28 2010-08-12 Husam Younes Biodegradable elastomers prepared by the condensation of an organic di-, tri- or tetra-carboxylic acid and an organic diol
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
EP2265645A4 (en) * 2008-03-13 2011-03-23 Perkinelmer Health Sci Inc ENZYMATIC SUBSTRATES FOR MULTIPLE DETECTION SYSTEMS
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
US20140274798A1 (en) 2013-03-15 2014-09-18 University Of Washington Through Its Center For Commercialization Compounds and methods relating to lysosomal storage disorders
AU2017225769B2 (en) 2016-03-02 2023-01-05 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
WO2018226854A2 (en) 2017-06-06 2018-12-13 Wayne State University Antifouling polymer coatings and reverse coating method
CN115177608B (zh) * 2022-07-26 2023-12-05 南方医科大学南方医院 长链酰基肉碱类化合物在制备预防和/或治疗肝癌的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
US5008288A (en) * 1986-01-06 1991-04-16 Alfred Stracher Carnitine directed pharmaceutical agents
IT1230142B (it) * 1989-05-03 1991-10-14 Fidia Spa Derivati della carnitina, processo per la loro preparazione e impiego in terapia umana
JPH05507929A (ja) * 1990-06-15 1993-11-11 ウェイク　フォレスト　ユニバーシティー エーテル脂質―ヌクレオシド共有結合体
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
IT1258370B (it) * 1992-03-02 1996-02-26 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil l-carnitine dotati di attivita' miorilassante selettiva sull'apparato gastro-intestinale e composizioni farmaceutiche che li contengono.
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
IT1263013B (it) * 1992-10-20 1996-07-23 Avantgarde Spa Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
IT1261984B (it) * 1993-06-22 1996-06-11 Avantgarde Spa Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
EP0706374B1 (en) * 1993-06-30 1997-12-10 Genentech, Inc. Method for preparing liposomes
IT1273987B (it) * 1994-09-29 1997-07-14 Sigma Tau Ind Farmaceuti Uso di esteri ftalidilidenici della carnitina e di alcanoil carnitine per il trattamento dello shock endotossico
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
WO1996040265A1 (en) * 1995-06-07 1996-12-19 The Regents Of The University Of California Stabilization of polynucleotide complexes
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
IT1283955B1 (it) * 1996-03-20 1998-05-07 Sigma Tau Ind Farmaceuti Bis alcanoil esteri della carnitina ad attivita' antibatterica, antimicotica ed antiprotozoaria.
EP0960204A4 (en) * 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
IT1299172B1 (it) * 1998-05-06 2000-02-29 Sigma Tau Ind Farmaceuti Esteri perfluorurati di alcanoil l-carnitine utilizzabili quali lipidi cationici per l'immissione intracellulare di composti

Also Published As

Publication number Publication date
DK1183228T3 (da) 2005-05-17
NO20085413L (no) 2001-10-12
AU2004224958A1 (en) 2004-11-25
US20070190128A1 (en) 2007-08-16
NO20014985L (no) 2001-10-12
WO2000061543A3 (en) 2001-01-11
CN1263730C (zh) 2006-07-12
HU229366B1 (en) 2013-11-28
DE60025961D1 (de) 2006-04-20
AU4312300A (en) 2000-11-14
IL175366A (en) 2010-12-30
KR100684378B1 (ko) 2007-02-20
BG65501B1 (bg) 2008-10-31
PT1183228E (pt) 2005-04-29
HUP0201446A3 (en) 2002-11-28
DE60017388T2 (de) 2006-03-30
CN100402017C (zh) 2008-07-16
KR20060113799A (ko) 2006-11-02
IL145765A0 (en) 2002-07-25
IT1306129B1 (it) 2001-05-30
IS6095A (is) 2001-09-28
ATE317257T1 (de) 2006-02-15
IL175366A0 (en) 2006-09-05
BR0009765A (pt) 2002-01-02
CA2650202A1 (en) 2000-10-19
EE05719B1 (et) 2014-08-15
ES2234591T3 (es) 2005-07-01
HRP20010740A2 (en) 2002-10-31
PL211710B1 (pl) 2012-06-29
ES2258688T3 (es) 2006-09-01
SI1183228T1 (en) 2005-04-30
US7585519B2 (en) 2009-09-08
BR0009765B1 (pt) 2013-11-05
BG109876A (en) 2008-02-29
EP1183228A2 (en) 2002-03-06
PT1426044E (pt) 2006-06-30
JP5420507B2 (ja) 2014-02-19
HK1045145B (zh) 2006-01-27
IL145765A (en) 2007-07-04
EA200300745A1 (ru) 2003-12-25
NZ515270A (en) 2004-02-27
PL351112A1 (en) 2003-03-24
KR20010113794A (ko) 2001-12-28
SK14312001A3 (sk) 2002-02-05
ITRM990220A1 (it) 2000-10-13
HUP0201446A2 (en) 2002-08-28
CZ302628B6 (cs) 2011-08-10
SI1426044T1 (sl) 2006-04-30
KR100798499B1 (ko) 2008-01-28
CA2650202C (en) 2012-12-11
EP1183228B1 (en) 2005-01-12
EP1435232A1 (en) 2004-07-07
AU2004224958B2 (en) 2007-11-22
EA006021B1 (ru) 2005-08-25
EE05514B1 (et) 2012-02-15
TR200202358T2 (tr) 2002-12-23
RS20090448A (xx) 2010-06-30
DK1426044T3 (da) 2006-06-12
BRPI0017460B1 (pt) 2016-04-19
IL185486A0 (en) 2008-01-06
AU776301B2 (en) 2004-09-02
RS52682B (en) 2013-08-30
ME00113B (me) 2010-10-10
IS2539B (is) 2009-09-15
JP4703855B2 (ja) 2011-06-15
EA004459B1 (ru) 2004-04-29
HRP20010740B1 (en) 2005-08-31
US7629003B2 (en) 2009-12-08
CA2370143C (en) 2011-06-21
RS50911B (sr) 2010-08-31
NZ528874A (en) 2005-09-30
JP2002541238A (ja) 2002-12-03
ATE286873T1 (de) 2005-01-15
YU70201A (sh) 2004-07-15
HK1092732A1 (en) 2007-02-16
EP1426044A1 (en) 2004-06-09
DE60025961T2 (de) 2006-08-17
NO20014985D0 (no) 2001-10-12
EE200100518A (et) 2002-12-16
NO336949B1 (no) 2015-11-30
CN1823731A (zh) 2006-08-30
TR200102941T2 (tr) 2002-05-21
SK287253B6 (sk) 2010-04-07
IS2476B (is) 2008-12-15
IS8719A (is) 2008-03-07
EE201100028A (et) 2011-08-15
BG65312B1 (bg) 2008-01-31
PL204418B1 (pl) 2010-01-29
SK288246B6 (sk) 2015-03-03
EA200101076A1 (ru) 2002-04-25
NO327742B1 (no) 2009-09-14
CZ20013617A3 (cs) 2002-02-13
US6797281B1 (en) 2004-09-28
BG105971A (en) 2002-08-30
ZA200109291B (en) 2002-08-16
MXPA01010359A (es) 2002-05-06
US20040186175A1 (en) 2004-09-23
US20050079209A1 (en) 2005-04-14
WO2000061543A2 (en) 2000-10-19
EP1426044B1 (en) 2006-02-08
CA2370143A1 (en) 2000-10-19
CN1359370A (zh) 2002-07-17
JP2011042657A (ja) 2011-03-03
HK1045145A1 (en) 2002-11-15
DE60017388D1 (de) 2005-02-17

Similar Documents

Publication Publication Date Title
MEP24008A (en) Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
TR200000737T2 (tr) İkame edilmiş kroman türevleri.
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
DE60003074D1 (de) Fusidinsäure-derivate
IT1299172B1 (it) Esteri perfluorurati di alcanoil l-carnitine utilizzabili quali lipidi cationici per l'immissione intracellulare di composti
CA2390631A1 (en) Carboxamide-substituted benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions